The role of public-sector research in the discovery of drugs and vaccines

New England Journal of Medicine

Volumn 364, Issue 6, 2011, Pages 535-541

  Stevens, Ashley J ^a   Jensen, Jonathan J ^a   Wyller, Katrine ^b   Kilgore, Patrick C ^c   Chatterjee, Sabarni ^d   Rohrbaugh, Mark L ^d  

^a BOSTON UNIVERSITY   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c BOSTON UNIVERSITY   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGIC FACTORS AND AGENTS ACTING ON THE IMMUNE SYSTEM; FLUOXETINE; NEW DRUG; NON PRESCRIPTION DRUG; VACCINE;

APPLIED RESEARCH; ARTICLE; BASIC RESEARCH; CANCER PREVENTION; DRUG APPROVAL; DRUG CLASSIFICATION; FOOD AND DRUG ADMINISTRATION; HUMAN; INFECTION; NEOPLASM; ORGANIZATION AND MANAGEMENT; PRIORITY JOURNAL; PUBLIC HEALTH; PUBLIC SECTOR RESEARCH INSTITUTION; THERAPY EFFECT; TREATMENT INDICATION; UNITED STATES;

EID: 79851477450     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsa1008268     Document Type: Article

References (26)

1. Cockburn I, Henderson R. Public-private interaction and the productivity of pharmaceutical research. (Working paper no. 6018.) Cambridge, MA: National Bureau of Economic Research, April 1997.
2. Zycher B, DiMasi JA, Milne C-P. Private sector contributions to pharmaceutical science: thirty-five summary case histories. Am J Ther 2010;17:101-20.
3. Toole AA. The impact of public basic research on industrial innovation: evidence from the pharmaceutical industry. New Brunswick, NJ: Rutgers University Department of Agricultural, Food and Resource Economics, 2008.
4. Drugs@FDA Glossary of Terms, U.S. Food and Drug Administration. (http://www.fda.gov/Drugs/InformationOnDrugs/ucm079436.htm#NewMolecularEntity.)
5. Loise V, Stevens AJ, The Bayh-Dole Act turns 30. Sci Transl Med 2010;2:52cm27.
6. Bremer H, Allen J, Latker NJ. The Bayh-Dole Act and revisionism redux. Patent Trademark Copyright Journal. August 14, 2009.
7. Graham B. Patent bill seeks shift to bolster innovation. Washington Post. April 8, 1978:M2.
8. Information on the government's right to assert ownership over federally funded inventions. Washington, DC: Government Accountability Office, 2009. (GAO-09-742.)
9. Innovation's golden goose. The Economist. December 14, 2002:3.
10. Allen JP. A long, hard journey: from Bayh-Dole to the Federal Technology Transfer Act. J Assoc Univ Tech Manag 2009;1: 21-32.
11. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151-85. (Pubitemid 36279392)
12. Kaitin KI, Bryant NR, Lasagna L. The role of the research-based pharmaceutical industry in medical progress in the United States. J Clin Pharmacol 1993;33:412-7. (Pubitemid 23169234)
13. Sampat BN. Academic patents and access to medicines in developing countries. Am J Public Health 2009;99:1-17.
14. Orange Book: approved drug products with therapeutic equivalence evaluations. Silver Spring, MD: Food and Drug Administration. (http://www.fda.gov/cder/ob.)
15. Kneller R. The importance of new companies for drug discovery: origins of a decade of new drugs. Nat Rev Drug Discov 2010;9:867-82. [Erratum, Nat Rev Drug Discov 2010;9:955.]
16. Association of University Technology Managers. (http://www.autm.net/ about/dsp.licensing-surveys.cfm)
17. Patent Foundation, University of Virginia. (http://uvapf.org/ presentations.)
18. DRI Capital home page. (http://www.dricapital.com.)
19. Paul Capital home page. (http://www.paulcap.com/InvestmentPlatforms/ Healthcare/PortfolioInvestmentsList.aspx.)
20. Royalty Pharma home page. (http://www.royaltypharma.com/index.php?option= com-content&view=article&id=55&Itemid=11.)
21. United States Patent and Trademark Office home page. (http://patft.uspto. gov.)
22. RECAP by Deloitte home page. (http://www.recap.com.)
23. Drugs@FDA home page. (http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm.)
24. Vaccines, blood & biologics. Silver Spring, MD: Food and Drug Administration. (http://www.fda.gov/Biologics BloodVaccines/default.htm.)
25. National Institutes of Health. Enacted appropriations for FY 2008-FY 2010. (http://officeofbudget.od.nih.gov/pdfs/FY11/ FY%202010%20Enacted%20Appropriations.pdf.)
26. Drug approvals and databases. Silver Spring, MD: Food and Drug Administration. (http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/ NDAApprovalsbyTherapeuticPotentialandChemicalType/default.htm.)